Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

Stopped Terminated due to the treatment environment for COVID-19 evolving with the pervasiveness of vaccinations and other therapeutic modalities in mitigating against severe infection that has eliminated a viable patient population for study enrollment.

Conditions

• Covid19
• Cytokine Release Syndrome

Interventions

• DRUG: dapansutrile capsules
• DRUG: placebo capsules

Sponsor

Olatec Therapeutics LLC

Collaborators

• [object Object]